David Zhen is an Oncology physician affiliated with University of Washington. OpenAlex indexes 120 publications with 1,199 citations (h-index 15); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
825 Eastlake Ave E
Seattle, WA 981094405
Telephone
206-606-7222Registry record last updated 21 Jul 2022.
Clinical trials
- Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Sponsor: University of Washington
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year20252 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
50.7%Serotonin-3 Receptor Antagonist25.4%Ondansetron Hcl100%Part D≥14 patientsOpioid Agonist25.4%Loperamide100%Part D≥13 patientsNervous system
28.4%Phenothiazine28.4%Prochlorperazine Maleate100%Part D≥13 patientsCardiovascular
20.9%Antiarrhythmic20.9%Lidocaine-Prilocaine100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Predictors of overall survival in advanced biliary tract cancer in the phase 3 TOPAZ-1 study
Hepatology Communications
2026 - Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Neal Futran, MD, DMD
University of Washington
Elizabeth Swisher
University of Washington
David Tirschwell
University of Washington
Elaine Peskind, MD
University of Washington
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”